Live Long and Prosper in These 10 US Counties

The median lifespan in the United States today is nearly 79 years. Like all medians and averages, your mileage may vary. In some U.S. towns and cities, the median falls to around 68, and in others, it rises to more than 85.

What’s different? It’s not just the air or the scenery. According to a report from Realtor.com, the road to a longer lifespan is not the same everywhere, but there are commonalities such as veggie-rich diets and plenty of exercise.

Dan Buettner, founder of a movement called Blue Zones that helps communities set policies to help residents live longer, comments, “If you want to live a long time, the best thing you can do is move to a place where people are verifiably living the longest.”

To come up with their list of U.S. counties where residents live the longest, researchers looked at death certificates in every U.S. country for 2014 to calculate life expectancy from birth. In the following longevity list, they’ve added population data for a notable city in the county and the median home listing price.

Summit County, Colorado
Median lifespan: 86.8 years
City: Breckinridge
Population: 30,585
Median home listing price: $930,500 Billings County, North Dakota
Median lifespan: 84 years
City: Medora
Population: 940
Median home listing price: $331,200 Marin County, California
Median lifespan: 83.8 years
City: San Rafael
Population: 260,651
Median home listing price: $1.43 million Fairfax County, Virginia
Median lifespan: 83.7 years
City: Herndon
Population: 1.15 million
Median home listing price: $608,700 Aleutians East Borough, Alaska
Median lifespan: 83.7 years
City: King Cove
Population: 3,370
Median home listing price: $226,500 Presidio County, Texas
Median lifespan: 83.7 years
City: Marfa
Population: 7,156
Median home listing price: $297,000 San Juan County, Washington
Median lifespan: 83.7 years
City: Friday Harbor
Population: 16,715
Median home listing price: $774,400 Los Alamos County, New Mexico
Median lifespan: 83.5 years
City: Los Alamos
Population: 18,738
Median home listing price: $384,400 Teton County, Wyoming
Median lifespan: 83.5 years
City: Jackson
Population: 23,265
Median home listing price: $1.3 million Collier County, Florida
Median lifespan: 83.4 years
City: Naples
Population: 372,880
Median home listing price: $479,400

More details and information are available at the Realtor.com website.

ALSO READ: The Most Popular Exercise Fad the Year You Were Born

 

Brokerages Expect Axalta Coating Systems Ltd (AXTA) to Announce $0.36 Earnings Per Share

Wall Street brokerages predict that Axalta Coating Systems Ltd (NYSE:AXTA) will post earnings of $0.36 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Axalta Coating Systems’ earnings, with the highest EPS estimate coming in at $0.39 and the lowest estimate coming in at $0.31. Axalta Coating Systems posted earnings of $0.31 per share during the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The firm is scheduled to issue its next earnings results on Thursday, August 2nd.

On average, analysts expect that Axalta Coating Systems will report full-year earnings of $1.31 per share for the current financial year, with EPS estimates ranging from $1.20 to $1.40. For the next financial year, analysts expect that the firm will post earnings of $1.50 per share, with EPS estimates ranging from $1.33 to $1.65. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Axalta Coating Systems.

Get Axalta Coating Systems alerts:

Axalta Coating Systems (NYSE:AXTA) last announced its quarterly earnings data on Wednesday, April 25th. The specialty chemicals company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.04. Axalta Coating Systems had a net margin of 0.94% and a return on equity of 20.56%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.14 billion. During the same quarter in the prior year, the company earned $0.26 EPS. Axalta Coating Systems’s revenue was up 15.7% compared to the same quarter last year.

Several analysts recently issued reports on AXTA shares. BMO Capital Markets started coverage on shares of Axalta Coating Systems in a research note on Tuesday, March 27th. They set a “market perform” rating and a $33.00 price objective for the company. Zacks Investment Research raised shares of Axalta Coating Systems from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Seaport Global Securities cut shares of Axalta Coating Systems from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 17th. JPMorgan Chase & Co. increased their price target on shares of Axalta Coating Systems from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, April 26th. Finally, Bank of America raised shares of Axalta Coating Systems from an “underperform” rating to a “neutral” rating and set a $35.00 price target for the company in a research note on Friday, April 27th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $34.13.

Shares of Axalta Coating Systems opened at $30.51 on Friday, according to MarketBeat Ratings. Axalta Coating Systems has a 12-month low of $27.77 and a 12-month high of $38.20. The stock has a market cap of $7.48 billion, a P/E ratio of 25.64, a price-to-earnings-growth ratio of 1.63 and a beta of 1.31. The company has a debt-to-equity ratio of 2.57, a current ratio of 2.26 and a quick ratio of 1.63.

In other news, VP Sean M. Lannon sold 3,892 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $31.12, for a total value of $121,119.04. Following the transaction, the vice president now directly owns 25,273 shares in the company, valued at approximately $786,495.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Steven R. Markevich sold 88,479 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $31.32, for a total transaction of $2,771,162.28. Following the completion of the transaction, the executive vice president now owns 323,875 shares in the company, valued at $10,143,765. The disclosure for this sale can be found here. In the last three months, insiders sold 604,588 shares of company stock valued at $18,910,751. Corporate insiders own 2.10% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Quantitative Systematic Strategies LLC acquired a new position in shares of Axalta Coating Systems in the 1st quarter worth approximately $288,000. Advisory Services Network LLC lifted its holdings in shares of Axalta Coating Systems by 5,102.0% in the 4th quarter. Advisory Services Network LLC now owns 22,941 shares of the specialty chemicals company’s stock worth $742,000 after acquiring an additional 22,500 shares during the last quarter. Harvest Management LLC acquired a new stake in Axalta Coating Systems during the 4th quarter worth approximately $955,000. Bronson Point Management LLC acquired a new stake in Axalta Coating Systems during the 4th quarter worth approximately $4,854,000. Finally, California Public Employees Retirement System lifted its holdings in Axalta Coating Systems by 10.8% during the 4th quarter. California Public Employees Retirement System now owns 380,954 shares of the specialty chemicals company’s stock worth $12,328,000 after buying an additional 37,019 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About Axalta Coating Systems

Axalta Coating Systems Ltd., through its subsidiaries, manufactures, markets, and distributes high performance coatings primarily for the transportation industry. It operates in two segments, Performance Coatings and Transportation Coatings. The Performance Coatings segment offers various specially-formulated water and solvent borne products and systems that are used to refinish damaged vehicles for independent body shops, multi-shop operators, and original equipment manufacturer (OEM) dealership body shops.

Get a free copy of the Zacks research report on Axalta Coating Systems (AXTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Finisar (FNSR) Getting Somewhat Positive Press Coverage, Analysis Finds

News coverage about Finisar (NASDAQ:FNSR) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Finisar earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the technology company an impact score of 48.3712393394037 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Get Finisar alerts: Free Research Report as EchoStar��s Revenues Jumped 16% (finance.yahoo.com) Riding The Finisar Waves (seekingalpha.com) Finisar Announces Fiscal 2018 Financial Results (finance.yahoo.com) Finisar Jumps Despite Weaker Than Expected Q4 Results (nasdaq.com) Finisar Stock Runs Into Familiar Resistance After Earnings (schaeffersresearch.com)

A number of research analysts have issued reports on the company. DA Davidson boosted their price target on Finisar to $26.00 and gave the stock a “buy” rating in a research report on Friday. Needham & Company LLC lowered Finisar from a “buy” rating to a “hold” rating and boosted their price target for the stock from $16.64 to $29.41 in a research report on Friday, March 9th. Morgan Stanley assumed coverage on Finisar in a research report on Friday, March 9th. They set an “equal weight” rating and a $21.00 price target for the company. B. Riley reiterated a “buy” rating and set a $17.50 price target (down previously from $18.00) on shares of Finisar in a research report on Friday, March 9th. Finally, Zacks Investment Research upgraded Finisar from a “sell” rating to a “hold” rating in a research report on Wednesday, May 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $24.83.

Shares of Finisar opened at $18.25 on Tuesday, MarketBeat reports. Finisar has a 12-month low of $14.25 and a 12-month high of $28.84. The company has a current ratio of 4.00, a quick ratio of 3.24 and a debt-to-equity ratio of 0.30. The firm has a market cap of $2.06 billion, a PE ratio of 57.03, a P/E/G ratio of 2.07 and a beta of 1.19.

Finisar (NASDAQ:FNSR) last posted its quarterly earnings data on Thursday, June 14th. The technology company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Finisar had a positive return on equity of 2.74% and a negative net margin of 3.67%. The company had revenue of $310.07 million for the quarter, compared to the consensus estimate of $309.93 million. During the same period in the prior year, the firm posted $0.50 earnings per share. The business’s revenue was down 13.3% on a year-over-year basis. equities research analysts predict that Finisar will post 0.62 EPS for the current fiscal year.

In other news, Director Roger C. Ferguson sold 3,000 shares of Finisar stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $17.30, for a total transaction of $51,900.00. Following the completion of the sale, the director now directly owns 28,784 shares of the company’s stock, valued at approximately $497,963.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerry S. Rawls sold 38,250 shares of Finisar stock in a transaction on Friday, June 1st. The stock was sold at an average price of $16.67, for a total transaction of $637,627.50. Following the sale, the director now directly owns 601,508 shares of the company’s stock, valued at $10,027,138.36. The disclosure for this sale can be found here. Insiders have sold a total of 109,458 shares of company stock valued at $1,728,950 over the last ninety days. 1.02% of the stock is currently owned by insiders.

Finisar Company Profile

Finisar Corporation provides optical subsystems and components for data communication and telecommunication applications in the United States, China, Malaysia, and internationally. The company's optical subsystems primarily include transmitters, receivers, transceivers, transponders, and active optical cables, which provide the fundamental optical-electrical, or optoelectronic interface for interconnecting the electronic equipment used in networks comprising switches, routers, and servers used in wireline networks, as well as antennas and base stations used in wireless networks.

AngloGold Ashanti (AU) Sets New 1-Year Low at $7.90

Shares of AngloGold Ashanti Limited (NYSE:AU) hit a new 52-week low during trading on Friday . The company traded as low as $7.90 and last traded at $8.15, with a volume of 45855965 shares. The stock had previously closed at $8.68.

A number of analysts have recently commented on AU shares. Zacks Investment Research downgraded AngloGold Ashanti from a “buy” rating to a “hold” rating in a research note on Thursday, February 15th. ValuEngine upgraded AngloGold Ashanti from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $10.75.

Get AngloGold Ashanti alerts:

The company has a quick ratio of 0.63, a current ratio of 1.57 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $3.54 billion, a P/E ratio of 135.83 and a beta of -0.88.

Institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Advisers LP boosted its stake in shares of AngloGold Ashanti by 41.4% in the fourth quarter. Two Sigma Advisers LP now owns 312,700 shares of the mining company’s stock worth $3,186,000 after buying an additional 91,600 shares during the last quarter. CoreCommodity Management LLC purchased a new position in AngloGold Ashanti during the fourth quarter worth approximately $665,000. Two Sigma Investments LP boosted its position in AngloGold Ashanti by 2,351.4% during the fourth quarter. Two Sigma Investments LP now owns 666,023 shares of the mining company’s stock worth $6,787,000 after purchasing an additional 638,854 shares in the last quarter. Alps Advisors Inc. boosted its position in AngloGold Ashanti by 33.6% during the first quarter. Alps Advisors Inc. now owns 535,456 shares of the mining company’s stock worth $5,081,000 after purchasing an additional 134,668 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in AngloGold Ashanti during the fourth quarter worth approximately $14,112,000. Hedge funds and other institutional investors own 32.93% of the company’s stock.

AngloGold Ashanti Company Profile

AngloGold Ashanti Limited operates as a gold mining company. The company also produces silver, uranium oxide, and sulphuric acid. Its portfolio includes 17 operations and 3 projects in 10 countries in South Africa, Continental Africa, the Americas, and Australasia. AngloGold Ashanti Limited was founded in 1944 and is headquartered in Johannesburg, South Africa.

Here's Why Acorda Therapeutics Rose as Much as 30.3% Today

What happened

Shares of Acorda Therapeutics (NASDAQ:ACOR) rose over 30% today after the company's lawyers made oral arguments in front of a panel at the U.S. Court of Appeals for the Federal Circuit late Thursday. The appeal was made in response to an earlier decision by a U.S. District Court to invalidate four of the company's patents for its multiple sclerosis drug Ampyra, which is the top revenue generator for the business and is expected to deliver at least $330 million in sales in 2018. That's down from $493 million in 2016.��

The timing is important. Acorda Therapeutics has one remaining patent on Ampyra, but it expires in July. That means the Federal Circuit decision on the appeal could be the difference between generic versions of the drug hitting the market this summer or sometime much later, perhaps as late as 2027.

As of 11:49 a.m. EDT, the stock had settled to a 22% gain.

Image source: Getty Images.

So what

The company didn't issue a press release or SEC filing because a decision on the appeal is still pending, but the higher-than-usual trading volume today indicates bullishness by an institutional investor or two about what was said during the arguments. Investors can listen to audio of the oral arguments in Acorda Therapeutics Inc. v. Roxane Laboratories Inc. that were made in front of the panel yesterday, although it may be difficult to draw conclusions one way or the other.

According to FiercePharma,�Acorda CEO Ron Cohen tried to quell angst among the company's sales representatives by stating that even if Ampyra loses intellectual property protections, the plan is to transfer everyone to accounts selling Parkinson's disease drug Inbrija. That's either a bullish comment on the drug's prospects, since it's currently awaiting a decision on marketing approval from the Food and Drug Administration, or exactly what investors would expect the CEO to say.

Now what

There's some degree of uncertainty surrounding Acorda Therapeutics right now. The month of June promises to be a volatile one for investors, considering that the Federal Circuit will soon decide whether or not to grant the company's appeal (and restore the invalidated Ampyra patents) and that the only currently valid patent expires in July. Today's move may be a bit premature, however, so investors should probably remain on the sidelines until more certainty is provided.